Q3 2023 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2023-11-14 · accession 0000950123-23-010821
$1.38B
Reported value
9
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | Moderna Inc | $998.4M | 72.5% | 9,666,038 | Common | SHARED |
| 799566104 | SANA | Sana Biotechnology Inc | $96.8M | 7.02% | 25,001,856 | Common | SHARED |
| 344174107 | FHTX | Foghorn Therapeutics Inc | $63.4M | 4.60% | 12,674,120 | Common | SHARED |
| 68217N105 | — | Omega Therapeutics Inc | $62.8M | 4.56% | 29,225,579 | Common | SHARED |
| 81750R102 | MCRB1EUR | Seres Therapeutics Inc | $55.0M | 3.99% | 23,117,045 | Common | SHARED |
| 24823R105 | DNLI | Denali Therapeutics Inc | $54.0M | 3.92% | 2,619,968 | Common | SHARED |
| 299734202 | EVLO | Evelo Biosciences Inc | $31.1M | 2.26% | 7,932,624 | Common | SHARED |
| 05454B204 | — | Axcella Health Inc | $12.2M | 0.89% | 1,170,059 | Common | SHARED |
| 87184Q206 | SYRS | Syros Pharmaceuticals Inc | $3.9M | 0.28% | 993,848 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.